Kayaaslan B, Guner R. COVID-19 and the liver: A brief and core review. World J Hepatol 2021; 13(12): 2013-2023 [PMID: 35070005 DOI: 10.4254/wjh.v13.i12.2013]
Corresponding Author of This Article
Bircan Kayaaslan, MD, Associate Professor, Department of Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara Yildirim Beyazit University, No. 1 Bilkent street, Çankaya District, Ankara 06800, Turkey. drbican@gmail.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Dec 27, 2021; 13(12): 2013-2023 Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2013
COVID-19 and the liver: A brief and core review
Bircan Kayaaslan, Rahmet Guner
Bircan Kayaaslan, Rahmet Guner, Department of Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara Yildirim Beyazit University, Ankara 06800, Turkey
Author contributions: Kayaaslan B contributed to conception and design of the review and writing of the manuscript; Guner R contributed to review and editing of the manuscript.
Conflict-of-interest statement: The authors declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bircan Kayaaslan, MD, Associate Professor, Department of Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara Yildirim Beyazit University, No. 1 Bilkent street, Çankaya District, Ankara 06800, Turkey. drbican@gmail.com
Received: May 18, 2021 Peer-review started: May 18, 2021 First decision: June 15, 2021 Revised: June 23, 2021 Accepted: November 27, 2021 Article in press: October 27, 2021 Published online: December 27, 2021 Processing time: 222 Days and 9.7 Hours
Core Tip
Core Tip: The study evaluated the incidence of liver injury in coronavirus disease 2019 (COVID-19) patients and its impact on clinical outcomes and pathophysiological mechanism of liver injury. More than one-fourth of COVID-19 patients had suffered from liver injury, mostly a mild-to-moderate liver dysfunction. Liver involvement is independently associated with adverse clinical outcomes. Direct viral cytotoxic effect, complications of the disease, and drugs used in the treatments are the pathophysiological mechanisms suggested for liver injury. However, the exact mechanism was not clearly explained. The actual cause should be carefully investigated in the presence of abnormal liver function tests, and appropriate treatments provided for possible factors.
